Zacks: Evolus (EOLS) Receives Average Rating of “Strong Buy” from Brokerages

Shares of Evolus (NASDAQ:EOLS) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price target of $22.50 for the company and are expecting that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also given Evolus an industry rank of 182 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently weighed in on EOLS shares. Mizuho started coverage on Evolus in a report on Monday, March 5th. They set a “buy” rating and a $21.00 price target for the company. JMP Securities started coverage on Evolus in a report on Monday, March 5th. They set an “outperform” rating and a $20.00 price target for the company. ValuEngine raised Evolus from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Cantor Fitzgerald initiated coverage on Evolus in a report on Monday, March 5th. They set an “overweight” rating and a $25.00 price target for the company. Finally, SunTrust Banks initiated coverage on Evolus in a research note on Monday, March 5th. They issued a “buy” rating and a $24.00 target price for the company.

EOLS stock traded up $0.12 during midday trading on Thursday, reaching $9.50. 5,446 shares of the company’s stock traded hands, compared to its average volume of 131,630. Evolus has a 1-year low of $7.53 and a 1-year high of $12.97. The stock has a market capitalization of $218.44 and a price-to-earnings ratio of -34.96.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Thursday, March 29th. The company reported $0.24 earnings per share for the quarter. equities research analysts forecast that Evolus will post -2.1 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Zacks: Evolus (EOLS) Receives Average Rating of “Strong Buy” from Brokerages” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/17/zacks-evolus-eols-receives-average-rating-of-strong-buy-from-brokerages.html.

About Evolus

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply